TiGenix Enrolls First Patient in Trial for Severe Sepsis Therapy
Crohn's Disease, News
Biopharmaceutical company TiGenix NV announced the enrollment of the first participant in their phase 1 study designed to assess Cx611 for treatment of severe sepsis. The trial will help advance the company’s development and commercialization of ... Read more